

Claudia Bighin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2373437/publications.pdf>

Version: 2024-02-01

33
papers

2,028
citations

567281

15
h-index

395702

33
g-index

33
all docs

33
docs citations

33
times ranked

2699
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 400-408.	6.3	15
2	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. <i>Tumori</i> , 2022, , 030089162110675.	1.1	1
3	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	5.2	6
4	The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 690320.	2.8	23
5	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	5.1	12
6	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020, 122, 1611-1617.	6.4	12
7	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51.	2.8	6
8	Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. <i>Clinical Medicine Insights Reproductive Health</i> , 2019, 13, 117955811986458.	3.9	20
9	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	13.7	260
10	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 474-485.	10.7	59
11	Management of young women with early breast cancer. <i>ESMO Open</i> , 2018, 3, e000458.	4.5	15
12	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. <i>Breast</i> , 2018, 41, 51-56.	2.2	41
13	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLEET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. <i>Oncologist</i> , 2017, 22, 648-654.	3.7	10
14	Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. <i>Breast</i> , 2017, 33, 104-108.	2.2	16
15	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	2.8	39
16	The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 346.	2.6	30
17	Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. <i>Oncotarget</i> , 2017, 8, 44800-44810.	1.8	4
18	Treatment with aromatase inhibitors and markers of cardiovascular disease. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 261-267.	2.5	7

#	ARTICLE	IF	CITATIONS
19	5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 117-126.	2.5	12
20	Pegfilgrastim administration after 24 or 72 or 96h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. <i>Supportive Care in Cancer</i> , 2016, 24, 1285-1294.	2.2	17
21	Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2632.	7.4	180
22	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2x2 factorial, randomised phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1863-1872.	13.7	164
23	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 675-683.	7.7	169
24	Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. <i>Breast</i> , 2013, 22, 470-475.	2.2	13
25	Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer patients. <i>Future Oncology</i> , 2013, 9, 955-957.	2.4	10
26	Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1391-1405.	2.4	19
27	Stevens-Johnson syndrome after treatment with bendamustine. <i>Leukemia Research</i> , 2012, 36, e153-e154.	0.8	11
28	Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 269-76.	7.4	311
29	Letrozole withdrawal response in locally advanced breast cancer. <i>Annals of Oncology</i> , 2011, 22, 1927-1928.	1.2	3
30	Use in current clinical practice of 70-gene signature in early breast cancer. <i>International Journal of Cancer</i> , 2010, 127, 2736-2737.	5.1	2
31	Estrone Sulphate, FSH, and Testosterone Levels in Two Male Breast Cancer Patients Treated with Aromatase Inhibitors. <i>Oncologist</i> , 2010, 15, 1270-1272.	3.7	13
32	Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 3859-3865.	1.6	505
33	Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. <i>Cancer</i> , 2003, 97, 1174-1180.	4.1	23